Adaptive Biotechnologies financials
$28.77+0.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $277.0M | $179.0M | $170.3M | $185.3M | $154.3M | $98.4M | $85.1M |
| Gross profit | $205.6M | $106.9M | $94.7M | $127.4M | $105.0M | $75.9M | $62.8M |
| Gross margin | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | 77.1% | 73.8% |
| Operating income | -$57.1M | -$162.5M | -$227.0M | -$200.2M | -$209.0M | -$152.8M | -$78.4M |
| Net income | -$59.5M | -$159.5M | -$225.3M | -$200.2M | -$207.3M | -$146.2M | -$69.6M |
| Net margin | −21.5% | −89.1% | −132.3% | −108.0% | −134.3% | −148.6% | −81.8% |
| Diluted EPS | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 | $-1.11 | $-1.01 |
| EBITDA | -$39.3M | -$136.1M | -$179.4M | -$179.3M | -$195.0M | -$144.3M | -$70.6M |
| Operating cash flow | -$46.0M | -$95.2M | -$156.3M | -$183.9M | -$192.7M | -$149.7M | $205.4M |
| Free cash flow | -$48.9M | -$98.9M | -$167.0M | -$200.3M | -$254.5M | -$168.5M | $194.2M |
| Diluted shares | 151.7M | 147.1M | 144.4M | 142.5M | 140.4M | 131.2M | 69.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $70.5M | $47.9M | $65.1M | $90.0M | $139.1M | $123.4M |
| Short-term investments | $156.5M | $174.4M | $281.3M | $408.2M | $214.0M | $564.8M |
| Total debt | $131.2M | $133.3M | $130.7M | $125.4M | $0.00 | $0.00 |
| Total assets | $512.7M | $539.4M | $661.1M | $856.6M | $923.3M | $1.12B |
| Total liabilities | $287.7M | $336.9M | $352.9M | $392.5M | $319.2M | $373.1M |
| Shareholders' equity | $225.0M | $202.5M | $308.3M | $464.1M | $604.1M | $743.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology